Eva SchaeferJansen - Sanofi ADR Head Relations
SNY Stock | USD 49.01 0.45 0.91% |
Insider
Eva SchaeferJansen is Head Relations of Sanofi ADR
Address | 46, avenue de la Grande Armée,, Paris, France, 75017 |
Phone | 33 1 53 77 40 00 |
Web | https://www.sanofi.com |
Sanofi ADR Management Efficiency
The company has Return on Asset of 0.0454 % which means that on every $100 spent on assets, it made $0.0454 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0727 %, implying that it generated $0.0727 on every 100 dollars invested. Sanofi ADR's management efficiency ratios could be used to measure how well Sanofi ADR manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.14 in 2024. Return On Capital Employed is likely to rise to 0.17 in 2024. At this time, Sanofi ADR's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 77.3 B in 2024, whereas Total Assets are likely to drop slightly above 88.2 B in 2024.Similar Executives
Showing other executives | INSIDER Age | ||
Victor Bulto | Novartis AG ADR | 46 | |
Vanessa Broadhurst | Johnson Johnson | 52 | |
Shobie Ramakrishnan | GlaxoSmithKline PLC ADR | 53 | |
Thomas Freyman | AbbVie Inc | 66 | |
Chris Sheldon | AstraZeneca PLC ADR | N/A | |
Tony Wood | GlaxoSmithKline PLC ADR | N/A | |
Deborah Eldracher | AstraZeneca PLC ADR | 59 | |
Risa LavizzoMourey | Merck Company | 66 | |
Bruno Eschli | Roche Holding Ltd | N/A | |
Claudia Bockstiegel | Roche Holding Ltd | 59 | |
Paul Penepent | Novartis AG ADR | N/A | |
Timothy Power | Bristol Myers Squibb | N/A | |
Gonzalo Vina | AstraZeneca PLC ADR | N/A | |
Dirk Brinckman | Johnson Johnson | N/A | |
A Washington | Johnson Johnson | 70 | |
Derica Rice | Bristol Myers Squibb | 56 | |
Tim Power | Bristol Myers Squibb | N/A | |
Nadim Ahmed | Bristol Myers Squibb | 51 | |
Thomas Hudson | AbbVie Inc | 62 | |
Linda Louie | Amgen Inc | N/A | |
Nadja West | Johnson Johnson | 60 |
Management Performance
Return On Equity | 0.0727 | ||||
Return On Asset | 0.0454 |
Sanofi ADR Leadership Team
Elected by the shareholders, the Sanofi ADR's board of directors comprises two types of representatives: Sanofi ADR inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sanofi. The board's role is to monitor Sanofi ADR's management team and ensure that shareholders' interests are well served. Sanofi ADR's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sanofi ADR's outside directors are responsible for providing unbiased perspectives on the board's policies.
Roy Papatheodorou, Executive Counsel | ||
FranoisXavier Roger, Chief Officer | ||
Paul Hudson, CEO Director | ||
Madeleine Roach, Executive Operations | ||
Pierre Chancel, Senior Marketing | ||
Bruno Mnard, Chief officer | ||
Dante Beccaria, Global VP | ||
Eva SchaeferJansen, Head Relations | ||
JeanBaptiste Chatillon, CFO, Executive Vice President Member of the Executive Committee | ||
Josephine Fubara, Chief Care | ||
Laurent Gilhodes, Principal Accounting | ||
Natalie Bickford, Executive Officer | ||
Josep Catlla, Head Communications |
Sanofi Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sanofi ADR a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0727 | ||||
Return On Asset | 0.0454 | ||||
Profit Margin | 0.1 % | ||||
Operating Margin | 0.18 % | ||||
Current Valuation | 71.22 B | ||||
Shares Outstanding | 2.5 B | ||||
Shares Owned By Institutions | 10.09 % | ||||
Number Of Shares Shorted | 3.24 M | ||||
Price To Earning | 7.78 X | ||||
Price To Book | 1.44 X |
Currently Active Assets on Macroaxis
When determining whether Sanofi ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanofi ADR's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanofi Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanofi Adr Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Sanofi Stock analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Stocks Directory Find actively traded stocks across global markets | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Earnings Share 1.94 | Revenue Per Share 18.492 | Quarterly Revenue Growth 0.023 | Return On Assets 0.0454 |
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.